戊型肝炎病毒(HEV)合成肽及基因重组抗原免疫反应性研究  

IMMUNOREACTIVITY STUDIES OF THE SYNTHETIC PEPTIDES AND RECOMBINANT ANTIGENS WITH SERA FROM PATIENTS INFECTED WITH HEPATITIS E VIRUS

作　　者：戎广亚[1] 孙杰[1] 周继文[1] 任继明[1] 赵桂兰[1] 雷祖才 张芳 王志杰[1] 王雪飞[1] 杨守纯[1] 

机构地区：[1]中国人民解放军第302医院

出　　处：《病毒学报》1998年第2期178-182,共5页Chinese Journal of Virology

摘　　要：用ＯＲＦ２、ＯＲＦ３合成肽抗原（１～１０号）及基因工程重组的ＯＲＦ２抗原（１和２号）分别建立了酶联免疫方法（ＥＩＡ），检测６０份戊型肝炎病人血清中ＨＥＶＩｇＧ及ＩｇＭ１０个合成肽抗原（Ｓｐ１－Ｓｐ１０）及２个重组抗原（Ｒｅ１、Ｒｅ２），均和ＨＥＶ阳性血清发生特异反应，但阳性率和反应强度差别很大。以Ｒｅ１（ＯＲＦ２，４０２～６６０）检测的抗体阳性率最高，为９６．７％（５８／６０）；Ｓｐ６（ＯＲＦ３，８８～１２３）次之，为９３．３％（５６／６０）；以上两种抗原混合使用阳性率为１００％（６０／６０）。Ｓｐ６、Ｒｅ１及这两种抗原混合使用检测抗ＨＥＶＩｇＭ，阳性率分别为１８．３％（１１／６０）、６６．７％（４０／６０）和６６．７％（４０／６０）。研究结果表明：合成肽６号（Ｓｐ６）及重组抗原１号（Ｒｅ１）是制备戊肝抗体诊断试剂的理想抗原。Solid-phase enzyme immunoassay(EIA) was developed for detecting anti-HEV IgG and IgM by using synthetic peptides Sp1-Sp10 from the open reading frame(ORF) 2,3 and recombinant antigens Re1,Re2 from ORF2.All of the synthetic peptides and recombinant antigens specifically reacted with sera of HEV-infected patients,but the positive rate and reactive intensity varied greatly.The positivity of the synthetic peptide 6 from ORF3(88-123),the recombinant antigen from ORF2(402-660) and the combined use of the above two antigens to anti-HEV IgG were 93.3%(56/60),96.7%(58/60),100%(60/60) and that to anti-HEV IgM were 18.3%(11/60),66.7%(40/60) and 66.7%(40/60) respectively.The data indicate that the combined use of synthetic peptide 6 and recombinant antigen 1 may be the promisimg antigens to develope a diagnostic reagent for detecting Hepatitis E.

关 键 词：戊型肝炎病毒 合成肽 重组抗原 免疫反应 

分 类 号：R373.21[医药卫生—病原生物学] R392.11[医药卫生—基础医学]